Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Author:

Chen Robert1,Gopal Ajay K.2,Smith Scott E.3,Ansell Stephen M.4,Rosenblatt Joseph D.5,Savage Kerry J.6,Connors Joseph M.6,Engert Andreas7,Larsen Emily K.8,Huebner Dirk9,Fong Abraham8,Younes Anas10

Affiliation:

1. City of Hope National Medical Center, Duarte, CA;

2. Division of Medical Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA;

3. Division of Hematology and Medical Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL;

4. Mayo Clinic, Rochester, MN;

5. Division of Hematology and Oncology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL;

6. British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada;

7. German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany;

8. Seattle Genetics, Inc., Bothell, WA;

9. Millenium Pharmaceuticals, Inc., Cambridge, MA; and

10. Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Key Points A total of 38% of patients who achieved CR (13 of 34) on brentuximab vedotin have remained in remission for >5 years and may be cured. Nine of the 13 patients (9% of all enrolled patients) have remained in long-term remission without a consolidative allogeneic transplant.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 326 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3